Compare PLETHICO PHARMA with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs LUPIN - Comparison Results

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA LUPIN PLETHICO PHARMA/
LUPIN
 
P/E (TTM) x -1.1 47.5 - View Chart
P/BV x 0.0 2.4 0.7% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PLETHICO PHARMA   LUPIN
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
LUPIN
Mar-19
PLETHICO PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs395986 40.1%   
Low Rs31720 4.3%   
Sales per share (Unadj.) Rs604.4369.5 163.6%  
Earnings per share (Unadj.) Rs32.513.4 242.3%  
Cash flow per share (Unadj.) Rs51.337.4 137.3%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs473.6303.7 155.9%  
Shares outstanding (eoy) m34.08452.49 7.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.42.3 15.3%   
Avg P/E ratio x6.663.6 10.3%  
P/CF ratio (eoy) x4.222.8 18.2%  
Price / Book Value ratio x0.52.8 16.0%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,262386,064 1.9%   
No. of employees `000NA17.7 0.0%   
Total wages/salary Rs m1,59631,513 5.1%   
Avg. sales/employee Rs ThNM9,453.8-  
Avg. wages/employee Rs ThNM1,782.0-  
Avg. net profit/employee Rs ThNM343.0-  
INCOME DATA
Net Sales Rs m20,598167,182 12.3%  
Other income Rs m3863,640 10.6%   
Total revenues Rs m20,984170,822 12.3%   
Gross profit Rs m2,81828,822 9.8%  
Depreciation Rs m64210,850 5.9%   
Interest Rs m1,5933,078 51.8%   
Profit before tax Rs m96918,534 5.2%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m0-3,400 0.0%   
Tax Rs m-1389,017 -1.5%   
Profit after tax Rs m1,1076,066 18.2%  
Gross profit margin %13.717.2 79.3%  
Effective tax rate %-14.348.7 -29.4%   
Net profit margin %5.43.6 148.1%  
BALANCE SHEET DATA
Current assets Rs m18,877138,536 13.6%   
Current liabilities Rs m11,89661,299 19.4%   
Net working cap to sales %33.946.2 73.4%  
Current ratio x1.62.3 70.2%  
Inventory Days Days3684 42.9%  
Debtors Days Days198112 175.9%  
Net fixed assets Rs m9,861127,516 7.7%   
Share capital Rs m341905 37.6%   
"Free" reserves Rs m12,331136,517 9.0%   
Net worth Rs m16,139137,422 11.7%   
Long term debt Rs m4,70666,417 7.1%   
Total assets Rs m33,146279,494 11.9%  
Interest coverage x1.67.0 22.9%   
Debt to equity ratio x0.30.5 60.3%  
Sales to assets ratio x0.60.6 103.9%   
Return on assets %8.13.3 249.0%  
Return on equity %6.94.4 155.4%  
Return on capital %12.38.9 137.9%  
Exports to sales %21.40-   
Imports to sales %15.20-   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,136NA-   
Fx inflow Rs m4,40259,414 7.4%   
Fx outflow Rs m3,18422,282 14.3%   
Net fx Rs m1,21937,132 3.3%   
CASH FLOW
From Operations Rs m2,43716,660 14.6%  
From Investments Rs m-6,265-32,825 19.1%  
From Financial Activity Rs m2,4907,441 33.5%  
Net Cashflow Rs m-1,337-8,724 15.3%  

Share Holding

Indian Promoters % 82.7 46.6 177.5%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 4.3 11.3 38.1%  
FIIs % 5.5 31.9 17.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 10.1 74.3%  
Shareholders   10,665 98,259 10.9%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   IPCA LABS  SANOFI INDIA  DR. DATSONS LABS  PROCTER & GAMBLE HEALTH  NOVARTIS  

Compare PLETHICO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

LUPIN LTD Announces Quarterly Results (2QFY19); Net Profit Down 31.1% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, LUPIN LTD has posted a net profit of Rs 3 bn (down 31.1% YoY). Sales on the other hand came in at Rs 40 bn (up 53.1% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS